To determine whether cyclic medroxyprogesterone treatment given without estrogen causes adverse symptoms in postmenopausal women.
Methods
This was a placebo-controlled, double-blind, crossover trial of 10 days/month of medroxyprogesterone and placebo treatments given during 2 consecutive months in random order. Participants recorded their physiologic and emotional experiences on a 0-4 scale using a daily diary form. Eleven postmenopausal women aged 43-63 completed the study. The subjects were not taking hormones. Height, weight, and serum estradiol concentration were measured once. In each woman, the sum of scores for the 10 days of medroxyprogesterone was compared to the sum of scores for the 10 days of placebo using nonparametric tests.
Results
No significant differences in scores were found between the 10 days on medroxyprogesterone and the 10 days on placebo. The median and range for the composite scores for premenstrual-like symptoms were 26 (20-67) during medroxyprogesterone and 25 (19-40) during placebo (P = .39).
Conclusions
Medroxyprogesterone given alone does not cause adverse symptoms in postmenopausal women. Therefore, medroxyprogesterone therapy, by itself, cannot explain the side effects reported by postmenopausal women taking combined hormones.
medroxyprogesterone without estrogen postmenopausal women adverse effects, Prior JC medroxyprogesterone placebo-controlled crossover trial, progesterone therapy alone postmenopausal symptoms safety, cyclic medroxyprogesterone postmenopausal double-blind placebo crossover, progestogen monotherapy postmenopausal women side effects, medroxyprogesterone premenstrual-like symptoms postmenopausal women, combined hormone therapy side effects progestogen attribution, medroxyprogesterone without estrogen emotional physiologic experiences, postmenopausal hormone therapy progestogen-only safety randomized, progesterone alone menopause treatment no adverse symptoms
Cite this article
Prior, J. C., Alojado, N., McKay, D. W., & Vigna, Y. M. (1994). No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, crossover trial. *Obstetrics and gynecology*, *83*(1), 24-28.
Prior JC, Alojado N, McKay DW, Vigna YM. No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, crossover trial. Obstet Gynecol. 1994;83(1):24-28.
Prior, J. C., et al. "No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, crossover trial." *Obstetrics and gynecology*, vol. 83, no. 1, 1994, pp. 24-28.
Hammarbäck S et al., 1988Acta Obstetricia Et Gynecologica Scandinavica
A treatment with the GnRH-agonist, buserelin, was given intranasally in a dosage of 400 micrograms once daily, to induce anovulation in 26 women with premenstrual tension syndrome; 23 patients complet...
Van der Meer YG et al., 1983Journal of Psychosomatic Obstetrics & Gynecology
A double-blind cross-over placebo controlled trial was carried out to compare progesterone 200 mg with a placebo, both given in rectal suppositories, in 20 patients with the pre-menstrual syndrome (PM...
For many patients with endometriosis, laparoscopic surgery is the most effective treatment to alleviate severe chronic pelvic pain and improve quality of life. Because endometriosis is common among in...
Endometriosis > Surgery > Fertility OutcomesRRM Methods > Debate and Controversy > Endometriosis Surgery ClaimsEthics/Philosophy > Medical Ethics > Reproductive Treatment Access
Dahlke JD et al., 2020
Open Access
Obstetrics and Gynecology
In this Commentary, we explain the case for a standardized cesarean delivery surgical technique. There are three strong arguments for a standardized approach to cesarean delivery, the most common majo...